Nana Brochmann1, Ann-Dorthe Zwisler2, Mette Kjerholt3, Esben Meulengracht Flachs4, Hans Carl Hasselbalch3, Christen Lykkegaard Andersen3. 1. Department of Haematology, Roskilde University Hospital, Koegevej 7-13, 4000, Roskilde, Denmark. nmor@regionsjaelland.dk. 2. National Centre for Rehabilitation and Palliation, University of Southern Denmark, and Odense University Hospital, Oester Farimagsgade 5A, 1353, Copenhagen, Denmark. 3. Department of Haematology, Roskilde University Hospital, Koegevej 7-13, 4000, Roskilde, Denmark. 4. National Institute of Public Health, University of Southern Denmark, Oester Farimagsgade 5A, 1353, Copenhagen, Denmark.
Abstract
PURPOSE: An Internet-based tool for reporting and analysing patient-reported outcomes (PROs) has been developed. The tool enables merging PROs with blood test results and allows for computation of treatment responses. Data may be visualized by graphical analysis and may be exported for downstream statistical processing. The aim of this study was to investigate, whether patients with myeloproliferative neoplasms (MPNs) were willing and able to use the tool and fill out questionnaires regularly. METHODS: Participants were recruited from the outpatient clinic at the Department of Haematology, Roskilde University Hospital, Denmark. Validated questionnaires that were used were European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, Myeloproliferative Neoplasm Symptom Assessment Form, Brief Fatigue Inventory and Short Form 36 Health Survey. Questionnaires were filled out ≥ 6 months online or on paper according to participant preference. Regularity of questionnaire submission was investigated, and participant acceptance was evaluated by focus-group interviews. RESULTS: Of 135 invited patients, 118 (87 %) accepted participation. One hundred and seven participants (91 %) preferred to use the Internet-based tool. Of the 118 enrolled participants, 104 (88 %) submitted PROs regularly ≥ 6 months. The focus-group interviews revealed that the Internet-based tool was well accepted. CONCLUSION: The Internet-based approach and regular collection of PROs are well accepted with a high participation rate, persistency and adherence in a population of MPN patients. The plasticity of the platform allows for adaptation to patients with other medical conditions.
PURPOSE: An Internet-based tool for reporting and analysing patient-reported outcomes (PROs) has been developed. The tool enables merging PROs with blood test results and allows for computation of treatment responses. Data may be visualized by graphical analysis and may be exported for downstream statistical processing. The aim of this study was to investigate, whether patients with myeloproliferative neoplasms (MPNs) were willing and able to use the tool and fill out questionnaires regularly. METHODS:Participants were recruited from the outpatient clinic at the Department of Haematology, Roskilde University Hospital, Denmark. Validated questionnaires that were used were European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, Myeloproliferative Neoplasm Symptom Assessment Form, Brief Fatigue Inventory and Short Form 36 Health Survey. Questionnaires were filled out ≥ 6 months online or on paper according to participant preference. Regularity of questionnaire submission was investigated, and participant acceptance was evaluated by focus-group interviews. RESULTS: Of 135 invited patients, 118 (87 %) accepted participation. One hundred and seven participants (91 %) preferred to use the Internet-based tool. Of the 118 enrolled participants, 104 (88 %) submitted PROs regularly ≥ 6 months. The focus-group interviews revealed that the Internet-based tool was well accepted. CONCLUSION: The Internet-based approach and regular collection of PROs are well accepted with a high participation rate, persistency and adherence in a population of MPN patients. The plasticity of the platform allows for adaptation to patients with other medical conditions.
Entities:
Keywords:
Feasibility study; Health-related quality of life; Internet-based tool; Myeloproliferative neoplasm; Patient-reported outcomes; Regular collection of patient-reported outcomes
Authors: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: Claire F Snyder; Albert W Wu; Robert S Miller; Roxanne E Jensen; Elissa T Bantug; Antonio C Wolff Journal: Cancer J Date: 2011 Jul-Aug Impact factor: 3.360
Authors: Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa Journal: Blood Date: 2011-05-02 Impact factor: 22.113
Authors: Vibe Skov; Mads Thomassen; Caroline H Riley; Morten K Jensen; Ole Weis Bjerrum; Torben A Kruse; Hans Carl Hasselbalch; Thomas Stauffer Larsen Journal: Exp Hematol Date: 2012-06-01 Impact factor: 3.084
Authors: A Coates; D Thomson; G R McLeod; P Hersey; P G Gill; I N Olver; R Kefford; R M Lowenthal; G Beadle; E Walpole Journal: Eur J Cancer Date: 1993 Impact factor: 9.162
Authors: Niels Henrik Ingvar Hjollund; Louise Pape Larsen; Karin Biering; Soren Paaske Johnsen; Erik Riiskjær; Liv Marit Schougaard Journal: Interact J Med Res Date: 2014-02-11
Authors: Youmin Cho; Yun Jiang; Huiting Zhang; Marcelline Ruth Harris; Yang Gong; Ellen Lavoie Smith Journal: J Med Internet Res Date: 2021-03-12 Impact factor: 5.428